Delivering DynamicARC on a clinical system
The recent DynamicARC tests are not just a milestone; they represent the beginning of a new chapter in proton therapy. Conducted in collaboration with Corewell Health, these tests are the first to demonstrate the technical feasibility of DynamicARC beam delivery on a clinical system, worldwide. IBA is the only proton therapy company to have conducted this type of tests, demonstrating the leadership of the company and its clinical and industrial partners in the arc proton therapy field. This innovative system was put to the test on an anthropomorphic phantom, where and it successfully irradiated a dozen plans using various treatment planning systems (TPS) that are either commercially available or in development, including Elekta ONE and RayStation. These results underscore the potential clinical applications of DynamicARC across a range of indications, including head and neck cancer, breast cancer, and abdominal cancers.
Discover here more information on the clinical indications that may benefit from DynamicARC.
Partnerships driving DynamicARC innovation
The successful execution of these tests underscores the critical partnerships between clinical and industrial entities and stands as a strong example of the unequaled achievements of the DynamicARC Consortium. These partnerships facilitate the sharing of expertise and resources, which ultimately enhances the capabilities of proton therapy and makes it accessible to more patients.
On one hand, collaborating with industry leaders like Elekta, RaySearch Laboratories and IBA Dosimetry has been and will remain essential in ensuring that the development of the DynamicARC system is aligned with the commercial availability of adapted TPS solutions at launch, and that quality assurance (QA) is optimized across delivery, with independent and automatic gantry follow-up. The recent tests have demonstrated the DynamicARC delivery from various TPS, including the Elekta ONE I Planning, powered by Moncao Monaco from Elekta, and the RayStation, which is under development by RaySearch Laboratories**.
On the other hand, clinical partners play a vital role in this journey. Their insights and experiences are invaluable in refining the DynamicARC technology and ensuring its effectiveness in clinical settings. The collaboration with Corewell Health’s William Beaumont University Hospital Proton Therapy Center gave the opportunity build and validate a full DynamicARC prototype based on their clinical system, and test some of the changes required to enable arc therapy, such as the new gantry controller and updated scanning controller.
A New Frontier in Proton Therapy
As highlighted by Dr. Deraniyagala, and Dr. Ding highlight, the worldwide premiere of the DynamicARC technical tests in a clinical setting at Beaumont marks an exciting time for proton therapy. With proven technical feasibility and strong partnerships with clinical and industry leaders, DynamicARC is one step closer to Proteus users and is set to shape the future of proton therapy for cancer patients.
Read more about how DynamicARC is set to become the next revolution in proton therapy here.
Notes
Disclaimer: The statements of the healthcare professional included in this testimonial reflect only his their opinion and personal experience. They do not necessarily reflect the opinion of any institution with whom he isthey are affiliated or IBA.
* DynamicARC is the registered brand of IBA’s Proton Arc therapy solution which is currently under research and development. DynamicARC will be available for sale when regulatory clearance is received. Due to a continuous research and development program, IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior notice. Some features are under development and may be subject to review by competent authorities.
** At the time of the tests, Elekta ONE I Planning was commercially available and Raystation was under development for DynamicARC delivery. Elekta ONE I Planning powered by Monaco has regulatory indications for use for DynamicARC. For more information, please contact your TPS provider.
